<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is a highly aggressive mature B-cell <z:hpo ids='HP_0002664'>neoplasm</z:hpo> comprising endemic, <z:hpo ids='HP_0003745'>sporadic</z:hpo> and <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo>-associated variants </plain></SENT>
<SENT sid="1" pm="."><plain>Human cell lines constitute a very useful tool to investigate the biology of lymphoid <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we succeeded in establishing two human cell lines, GAL-01 and GAL-02, from a HIV-negative patient with Epstein-Barr virus (EBV) -negative <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> presenting as an effusion </plain></SENT>
<SENT sid="3" pm="."><plain>GAL-01 and GAL-02 were established at diagnosis and after one course of polychemotherapy, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The in vivo effusion occurred in a very peculiar clinical setting; the patient having a previous history of intestinal diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: The morphologic, immunophenotypic and molecular genetic features of GAL cell lines are reported and compared with those of the parental <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The findings clearly demonstrated that the Burkitt effusion did not represent disease progression of the <z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">intestinal tumour</z:e>, but represented a second primary <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancy</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The in vivo tumorigenic properties of the cells were tested by subcutaneous injection to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>/<z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Both cell lines were composed of medium-sized lymphoid cells with clumped chromatin, multiple medium-sized nucleoli and moderate amounts of vacuolated cytoplasm </plain></SENT>
<SENT sid="9" pm="."><plain>GAL cells display the phenotype and genotype of a B-cell lineage (positive for CD20, CD79a and clonal rearrangement of Ig heavy chain), carry the c-MYC rearrangement by t(8;22)(q24;q11) translocation and are characterised by the expression of the germinal centre-associated antigens CD10, BCL6, CD38 and absent to low BCL2 expression </plain></SENT>
<SENT sid="10" pm="."><plain>EBV and HHV8 were not identified within parental <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> or in cultured cells </plain></SENT>
<SENT sid="11" pm="."><plain>Subcutaneous injection of both cell lines to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>/<z:mp ids='MP_0002536'>SCID</z:mp> mice induced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> formation </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: GAL-01 and GAL-02, two novel EBV-negative human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines represent a potentially useful experimental model to study the biology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> possibly including the resistance to chemotherapy </plain></SENT>
</text></document>